Literature DB >> 10215015

HLA DR2 and DQ1 frequency among narcoleptic patients in Hong Kong Chinese.

Y K Wing1, C N Chen, C K Ho.   

Abstract

Narcolepsy is a life-long crippling sleep disorder with significant physical and psychosocial impairments. Although its exact etiology and neuropathology is not clear, a strong association with specific human leucocyte antigen (HLA) subtype, particularly DR2 (DRw15) and DQw1 (DQw6), has been demonstrated across different ethnic groups including Caucasians and Japanese. The presence of 100% association with HLA DR2 in a series of Hong Kong Chinese narcoleptic patients has previously been reported. The report can now be extended, and as far as could be ascertained in the available subjects, all were HLA DQw1 (DQw6)-positive. This is concordant with the experiences of Japanese narcoleptic patients who are 100% HLA DR2- and DQw1-positive. However, the definitive account of the population prevalence of narcolepsy in Chinese could be determined only by a well-conducted epidemiological study with laboratory confirmation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10215015     DOI: 10.1046/j.1440-1819.1998.00423.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  2 in total

1.  The familial risk and HLA susceptibility among narcolepsy patients in Hong Kong Chinese.

Authors:  Lei Chen; S Y Y Fong; Ching W Lam; Nelson L S Tang; Margaret H L Ng; Albert M Li; C K W Ho; Suk-Hang Cheng; Kin-Mang Lau; Yun Kwok Wing
Journal:  Sleep       Date:  2007-07       Impact factor: 5.849

2.  Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.

Authors:  Tomoko Kobayashi; Shintaro Iwama; Daisuke Sugiyama; Yoshinori Yasuda; Takayuki Okuji; Masaaki Ito; Sachiko Ito; Mariko Sugiyama; Takeshi Onoue; Hiroshi Takagi; Daisuke Hagiwara; Yoshihiro Ito; Hidetaka Suga; Ryoichi Banno; Hiroyoshi Nishikawa; Hiroshi Arima
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.